Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Additional risk factors commonly present in patients prescribed GLP-1 receptor agonists include: Reduced physical activity and prolonged immobility Hypertension and other cardiovascular comorbidities Dyslipidaemia contributing to atherosclerosis Advanced age , as thrombotic risk increases with ageing Other important VTE risk factors include: Previous VTE or family history of clotting disorders Thrombophilia (inherited or acquired clotting disorders) Active cancer or cancer treatment Oestrogen-containing medications (HRT, combined oral contraceptives) Pregnancy and postpartum period Recent surgery, trauma or hospitalisation Long-haul travel with prolonged immobility Smoking When patients taking GLP-1 receptor agonists experience thrombotic events, it is important to consider these pre-existing risk factors as they often contribute significantly to clotting risk in this population
Your provider may not prescribe you topiramate if you are pregnant, trying to conceive, or breastfeeding
KJ Lenton, AT San, H Therriault, AM Cantin, H Payette, JR Wagner
By product type, oral GLP-1 receptor agonists segment is expected to grow at the fastest rate over the forecast period
Pulmonary arterial hypertension: pathogenesis and clinical management
